The truth about drug innovation; new report from Tufts

A new report from the USA's Tufts Center for the Study of Drug Development, examines case histories for 35 important pharmaceutical innovations. Skeptics of the private industry assert that the development of new medicines is most attributable to publicly funded sources.

As Marcia Angell, former editor-in-chief of The New England Journal of Medicine, remarked during an interview with PBS News : "innovation comes mainly from National Institutes of Health-supported research in academic medical centers. The drug companies do almost no innovation."

In this new study, the authors debunk this assertion and argue that the private sector plays a critical role in drug development. Its key findings include: NIH-sponsored research tends to be concentrated on the basic science of disease biology, biochemistry, and disease processes, the goal of which is to identify biologic targets that might prove vulnerable to drugs yet to be developed. Private sector contributions are weighted heavily toward the applied science of discovering ways to pursue treatments and cures for adverse medical conditions. For more, go to: www.manhattan-institute.org.pfd/mpr_06_emb.pfd.